Pharmaceutical

AbbVie and FutureGen link on inflammatory bowel disease

AbbVie has made a licence agreement with FutureGen Biopharmaceutical for developing FG-M701 for inflammatory bowel disease (IBD).

Jun 16, 2024 - 04:00
AbbVie and FutureGen link on inflammatory bowel disease
AbbVie has made a licence agreement with FutureGen Biopharmaceutical for developing FG-M701 for inflammatory bowel disease (IBD).
Read the original article

Tags:

Previous Article

Suven Pharmaceuticals to gain controlling stake in Sapala Organics

Next Article

UK’s new Netflix-style funding model for antibiotics goes live

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

J&J drops Addex’s epilepsy treatment after flunking in Phase II

J&J drops Addex’s epilepsy treatment after flunking in ...

Jul 24, 2024

STAT+: Pharmalittle: Three big drugmakers spent less on lobbying after leaving PhRMA; EMA reviews CRO over data concerns

STAT+: Pharmalittle: Three big drugmakers spent less on...

Jul 24, 2023

Zealand raises DKr1.45bn to advance obesity pipeline

Zealand raises DKr1.45bn to advance obesity pipeline

Jan 9, 2024